Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Optimind Pharma Corp. (CSE: OMND) (the " Optimind " or the " Company ") announces that it has entered into a non-binding letter of intent dated March 18, 2025, (the " LOI ") to acquire all of the issued and outstanding shares (the " Transaction ") of Monjin Interviews Private Limited (" Monjin "), a corporation formed under the laws of India. The Transaction is an arm's... Read More

Toronto, Ontario--(Newsfile Corp. - July 29, 2024) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces it has closed the second trance of its previously announced private placement. The Company issued 2,500,000 common shares at a price of $0.05 per share to investors for gross proceeds of $125,000. The Company expects to close a third tranche of the private placement in the next couple of weeks. Net... Read More

Toronto, Ontario--(Newsfile Corp. - July 8, 2024) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces it has closed the first trance of its previously announced private placement. The Company issued 2,900,000 common shares at a price of $0.05 per share to investors for gross proceeds of $145,000. The Company expects to close a second tranche of the private placement in the next couple of weeks. Net... Read More

Toronto, Ontario--(Newsfile Corp. - July 3, 2024) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces a proposed private placement. The Company intends to issue up to 10,000,000 common shares (the "Shares") at a price of $0.05 per share for gross proceeds of up to $500,000. Net proceeds will be used for working capital. All securities issued in connection with the private placement will be subject... Read More

TORONTO, ON / ACCESSWIRE / December 19, 2023 / Optimind Pharma Corp. (CSE:OMND) ("Optimind" or the "Company"), an emerging provider of psychedelic therapies, is pleased to announce that Manitari Pharma Corporation ("Manitari") has received its Controlled Drug and Substances Dealer's License ("Dealer's License") on December 8, 2023. This license allows Manitari to process psilocybin and psilocin, the active compounds derived... Read More

TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") is pleased to announce that it has entered into an acquisition agreement dated October 12, 2023 (the "Agreement") with Wolf Acquisitions 1.0 Corp. ("Wolf"), an arm's length private British Columbia corporation, and 1443885 B.C. Ltd. ("Subco"), a wholly-owned subsidiary of the Company, pursuant to which Optimind will... Read More

Toronto, Ontario--(Newsfile Corp. - March 10, 2023) - Optimind Pharma Corp. (CSE: OMND) (the "Company") wishes to announce that pursuant to its stock option plan, it has granted stock options to its directors, officers and consultants on March 8, 2023 to purchase up to 5,900,000 common shares of the Company at an exercise price of $0.05 per common share. The options have a term of four (4) years expiring on March 8, 2027.... Read More